A phase I clinical trial of systemically delivered NEMO binding domain peptide in dogs with spontaneous activated B-cell like diffuse large B-cell lymphoma.
Activated B-Cell (ABC) Diffuse Large B-Cell Lymphoma (DLBCL) is a common, aggressive and poorly chemoresponsive subtype of DLBCL, characterized by constitutive canonical NF-κB signaling. Inhibition of NF-κB signaling leads to apoptosis of ABC-DLBCL cell lines, suggesting targeted disruption of this...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2014
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/4e5bee67ecdb4a43b058c8a7e1188110 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:4e5bee67ecdb4a43b058c8a7e1188110 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:4e5bee67ecdb4a43b058c8a7e11881102021-11-18T08:20:45ZA phase I clinical trial of systemically delivered NEMO binding domain peptide in dogs with spontaneous activated B-cell like diffuse large B-cell lymphoma.1932-620310.1371/journal.pone.0095404https://doaj.org/article/4e5bee67ecdb4a43b058c8a7e11881102014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24798348/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203Activated B-Cell (ABC) Diffuse Large B-Cell Lymphoma (DLBCL) is a common, aggressive and poorly chemoresponsive subtype of DLBCL, characterized by constitutive canonical NF-κB signaling. Inhibition of NF-κB signaling leads to apoptosis of ABC-DLBCL cell lines, suggesting targeted disruption of this pathway may have therapeutic relevance. The selective IKK inhibitor, NEMO Binding Domain (NBD) peptide effectively blocks constitutive NF-κB activity and induces apoptosis in ABC-DLBCL cells in vitro. Here we used a comparative approach to determine the safety and efficacy of systemic NBD peptide to inhibit constitutive NF-κB signaling in privately owned dogs with spontaneous newly diagnosed or relapsed ABC-like DLBCL. Malignant lymph nodes biopsies were taken before and twenty-four hours after peptide administration to determine biological effects. Intravenous administration of <2 mg/kg NBD peptide was safe and inhibited constitutive canonical NF-κB activity in 6/10 dogs. Reductions in mitotic index and Cyclin D expression also occurred in a subset of dogs 24 hours post peptide and in 3 dogs marked, therapeutically beneficial histopathological changes were identified. Mild, grade 1 toxicities were noted in 3 dogs at the time of peptide administration and one dog developed transient subclinical hepatopathy. Long term toxicities were not identified. Pharmacokinetic data suggested rapid uptake of peptide into tissues. No significant hematological or biochemical toxicities were identified. Overall the results from this phase I study indicate that systemic administration of NBD peptide is safe and effectively blocks constitutive NF-κB signaling and reduces malignant B cell proliferation in a subset of dogs with ABC-like DLBCL. These results have potential translational relevance for human ABC-DLBCL.Georges Habineza NdikuyezeAnita Gaurnier-HausserReema PatelAlbert S BaldwinMichael J MayPatrick FloodErika KrickKathleen J PropertNicola J MasonPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 5, p e95404 (2014) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Georges Habineza Ndikuyeze Anita Gaurnier-Hausser Reema Patel Albert S Baldwin Michael J May Patrick Flood Erika Krick Kathleen J Propert Nicola J Mason A phase I clinical trial of systemically delivered NEMO binding domain peptide in dogs with spontaneous activated B-cell like diffuse large B-cell lymphoma. |
| description |
Activated B-Cell (ABC) Diffuse Large B-Cell Lymphoma (DLBCL) is a common, aggressive and poorly chemoresponsive subtype of DLBCL, characterized by constitutive canonical NF-κB signaling. Inhibition of NF-κB signaling leads to apoptosis of ABC-DLBCL cell lines, suggesting targeted disruption of this pathway may have therapeutic relevance. The selective IKK inhibitor, NEMO Binding Domain (NBD) peptide effectively blocks constitutive NF-κB activity and induces apoptosis in ABC-DLBCL cells in vitro. Here we used a comparative approach to determine the safety and efficacy of systemic NBD peptide to inhibit constitutive NF-κB signaling in privately owned dogs with spontaneous newly diagnosed or relapsed ABC-like DLBCL. Malignant lymph nodes biopsies were taken before and twenty-four hours after peptide administration to determine biological effects. Intravenous administration of <2 mg/kg NBD peptide was safe and inhibited constitutive canonical NF-κB activity in 6/10 dogs. Reductions in mitotic index and Cyclin D expression also occurred in a subset of dogs 24 hours post peptide and in 3 dogs marked, therapeutically beneficial histopathological changes were identified. Mild, grade 1 toxicities were noted in 3 dogs at the time of peptide administration and one dog developed transient subclinical hepatopathy. Long term toxicities were not identified. Pharmacokinetic data suggested rapid uptake of peptide into tissues. No significant hematological or biochemical toxicities were identified. Overall the results from this phase I study indicate that systemic administration of NBD peptide is safe and effectively blocks constitutive NF-κB signaling and reduces malignant B cell proliferation in a subset of dogs with ABC-like DLBCL. These results have potential translational relevance for human ABC-DLBCL. |
| format |
article |
| author |
Georges Habineza Ndikuyeze Anita Gaurnier-Hausser Reema Patel Albert S Baldwin Michael J May Patrick Flood Erika Krick Kathleen J Propert Nicola J Mason |
| author_facet |
Georges Habineza Ndikuyeze Anita Gaurnier-Hausser Reema Patel Albert S Baldwin Michael J May Patrick Flood Erika Krick Kathleen J Propert Nicola J Mason |
| author_sort |
Georges Habineza Ndikuyeze |
| title |
A phase I clinical trial of systemically delivered NEMO binding domain peptide in dogs with spontaneous activated B-cell like diffuse large B-cell lymphoma. |
| title_short |
A phase I clinical trial of systemically delivered NEMO binding domain peptide in dogs with spontaneous activated B-cell like diffuse large B-cell lymphoma. |
| title_full |
A phase I clinical trial of systemically delivered NEMO binding domain peptide in dogs with spontaneous activated B-cell like diffuse large B-cell lymphoma. |
| title_fullStr |
A phase I clinical trial of systemically delivered NEMO binding domain peptide in dogs with spontaneous activated B-cell like diffuse large B-cell lymphoma. |
| title_full_unstemmed |
A phase I clinical trial of systemically delivered NEMO binding domain peptide in dogs with spontaneous activated B-cell like diffuse large B-cell lymphoma. |
| title_sort |
phase i clinical trial of systemically delivered nemo binding domain peptide in dogs with spontaneous activated b-cell like diffuse large b-cell lymphoma. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2014 |
| url |
https://doaj.org/article/4e5bee67ecdb4a43b058c8a7e1188110 |
| work_keys_str_mv |
AT georgeshabinezandikuyeze aphaseiclinicaltrialofsystemicallydeliverednemobindingdomainpeptideindogswithspontaneousactivatedbcelllikediffuselargebcelllymphoma AT anitagaurnierhausser aphaseiclinicaltrialofsystemicallydeliverednemobindingdomainpeptideindogswithspontaneousactivatedbcelllikediffuselargebcelllymphoma AT reemapatel aphaseiclinicaltrialofsystemicallydeliverednemobindingdomainpeptideindogswithspontaneousactivatedbcelllikediffuselargebcelllymphoma AT albertsbaldwin aphaseiclinicaltrialofsystemicallydeliverednemobindingdomainpeptideindogswithspontaneousactivatedbcelllikediffuselargebcelllymphoma AT michaeljmay aphaseiclinicaltrialofsystemicallydeliverednemobindingdomainpeptideindogswithspontaneousactivatedbcelllikediffuselargebcelllymphoma AT patrickflood aphaseiclinicaltrialofsystemicallydeliverednemobindingdomainpeptideindogswithspontaneousactivatedbcelllikediffuselargebcelllymphoma AT erikakrick aphaseiclinicaltrialofsystemicallydeliverednemobindingdomainpeptideindogswithspontaneousactivatedbcelllikediffuselargebcelllymphoma AT kathleenjpropert aphaseiclinicaltrialofsystemicallydeliverednemobindingdomainpeptideindogswithspontaneousactivatedbcelllikediffuselargebcelllymphoma AT nicolajmason aphaseiclinicaltrialofsystemicallydeliverednemobindingdomainpeptideindogswithspontaneousactivatedbcelllikediffuselargebcelllymphoma AT georgeshabinezandikuyeze phaseiclinicaltrialofsystemicallydeliverednemobindingdomainpeptideindogswithspontaneousactivatedbcelllikediffuselargebcelllymphoma AT anitagaurnierhausser phaseiclinicaltrialofsystemicallydeliverednemobindingdomainpeptideindogswithspontaneousactivatedbcelllikediffuselargebcelllymphoma AT reemapatel phaseiclinicaltrialofsystemicallydeliverednemobindingdomainpeptideindogswithspontaneousactivatedbcelllikediffuselargebcelllymphoma AT albertsbaldwin phaseiclinicaltrialofsystemicallydeliverednemobindingdomainpeptideindogswithspontaneousactivatedbcelllikediffuselargebcelllymphoma AT michaeljmay phaseiclinicaltrialofsystemicallydeliverednemobindingdomainpeptideindogswithspontaneousactivatedbcelllikediffuselargebcelllymphoma AT patrickflood phaseiclinicaltrialofsystemicallydeliverednemobindingdomainpeptideindogswithspontaneousactivatedbcelllikediffuselargebcelllymphoma AT erikakrick phaseiclinicaltrialofsystemicallydeliverednemobindingdomainpeptideindogswithspontaneousactivatedbcelllikediffuselargebcelllymphoma AT kathleenjpropert phaseiclinicaltrialofsystemicallydeliverednemobindingdomainpeptideindogswithspontaneousactivatedbcelllikediffuselargebcelllymphoma AT nicolajmason phaseiclinicaltrialofsystemicallydeliverednemobindingdomainpeptideindogswithspontaneousactivatedbcelllikediffuselargebcelllymphoma |
| _version_ |
1718421859540664320 |